Mabion S.A. is hosting a biologics development and manufacturing program event on October 6-8 at Booth 12F33
Published
Signal category
Presence & Recognition
Quote
“October 6-8”
— Mabion S.A. team
Company
Mabion S.A.
Your Biologics Partner
- Industry
- Pharmaceutical Manufacturing
- Location
- Konstantynów Łódzki, PL
- Company size
- 168 employees
Mabion Biologics is a Poland-based biologics company specializing in the development and GMP manufacturing of large-molecule therapeutics, including monoclonal antibodies, biosimilars, recombinant proteins, and emerging complex biologics (like bispecifics or ADCs). The company provides services covering cell line development, upstream and downstream bioprocessing, analytical development, quality control, logistics, clinical and commercial manufacturing. Mabion gained international recognition through its participation in recombinant spike antigen manufacturing activities related to the Novavax COVID-19 vaccine program. Mabion is a highly specialized European Drug Substance development and manufacturing partner focused on large molecule manufacturing, biosimilar programs, innovation-driven collaborations, and strategic co-development partnerships. The company aims to become the most flexible and technologically advanced large molecule CDMO for biologics in Europe, with strategic focus areas including ADCs, bispecific antibodies, highly potent biologics, biosimilars, and innovative CD20-based projects. Mabion S.A. is a public Company, listed on the Warsaw Stock Exchange (WSE: MAB). For more information about the Company, please visit www.mabion.eu
Founded 2007